carbapenems has been researched along with Hospital Acquired Pneumonia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 8 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Nathanson, BH; Puzniak, LA; Shorr, AF; Zilberberg, MD | 1 |
| Chan, MC; Chen, CM; Chen, CY; Feng, JY; Liang, SJ; Lin, YC; Peng, CK; Sheu, CC; Wang, SH; Yang, KY; Zheng, ZR | 1 |
| Ahmed, W; Al-Hamzi, MA; Al-Turkistani, HH; Aljishi, Y; Almaghrabi, RS; Alodini, K; Alosaimi, R; Alraddadi, BM; Alshukairi, AN; Alswaiel, R; Althaqafi, A; Anani, M; Attalah, D; Eljaaly, K; Hassan, W; Heaphy, ELG; Hefni, LK; Qutub, MO; Saeedi, MF | 1 |
| Jiang, J; Liu, X; Long, Y; Qiao, L; Wang, Q; Wu, J; Xu, T; Yang, Y; Yu, J; Zhang, B; Zuo, W | 1 |
| Chen, WC; Cheng, HY; Hung, CC; Lin, MH; Lin, YC; Shen, YC; Teng, CK | 1 |
| Howatt, M; Kalil, AC; Klompas, M; Metersky, ML; Muscedere, J | 1 |
| Chan, MC; Chen, CM; Feng, JY; Lin, YC; Lin, YT; Peng, CK; Shen, YC; Sheu, CC; Wang, SH; Yang, KY; Zheng, ZR | 1 |
| Rhodes, NJ; Wunderink, RG | 1 |
| Jett, R; Lopez, J; O'Donnell, JN; Rhodes, NJ; Scheetz, MH | 1 |
| Guo, Z; Tang, X; Wang, L; Wang, Q; Xiao, S; Zhou, K; Zhuo, C | 1 |
| Fan, W; Nathanson, BH; Shorr, AF; Sulham, K; Zilberberg, MD | 1 |
3 review(s) available for carbapenems and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Intraabdominal Infections; Network Meta-Analysis; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2023 |
Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Critical Care; Drug Resistance, Multiple, Bacterial; Healthcare-Associated Pneumonia; Humans; Treatment Outcome | 2021 |
Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Healthcare-Associated Pneumonia; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Odds Ratio; Pseudomonas aeruginosa; Randomized Controlled Trials as Topic; Risk Factors; Staphylococcus aureus; Survival Analysis; Treatment Outcome | 2018 |
8 other study(ies) available for carbapenems and Hospital Acquired Pneumonia
| Article | Year |
|---|---|
Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019.
Topics: Anti-Bacterial Agents; Carbapenems; Escherichia coli; Healthcare-Associated Pneumonia; Hospitals; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Retrospective Studies; Staphylococcus aureus; United States; Ventilators, Mechanical | 2022 |
Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Critical Illness; Cross Infection; Gram-Negative Bacteria; Healthcare-Associated Pneumonia; Humans; Retrospective Studies | 2022 |
Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Enterobacteriaceae Infections; Escherichia coli; Female; Healthcare-Associated Pneumonia; Humans; Male; Middle Aged; Molecular Epidemiology; Prospective Studies; Saudi Arabia | 2022 |
Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Critical Illness; Cross Infection; Healthcare-Associated Pneumonia; Humans; Polymyxin B; Retrospective Studies; Sulbactam; Tigecycline | 2023 |
Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2021 |
Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Healthcare-Associated Pneumonia; Humans | 2021 |
An Emerging Clone (ST457) of Acinetobacter baumannii Clonal Complex 92 With Enhanced Virulence and Increasing Endemicity in South China.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Animals; Bacterial Typing Techniques; Carbapenems; China; Endemic Diseases; Evolution, Molecular; Female; Genomics; Healthcare-Associated Pneumonia; Humans; Larva; Male; Middle Aged; Moths; Multilocus Sequence Typing; Prevalence; Virulence; Virulence Factors; Whole Genome Sequencing | 2018 |
A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study.
Topics: Algorithms; beta-Lactam Resistance; Carbapenems; Costs and Cost Analysis; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Length of Stay; Male; Middle Aged; Outcome and Process Assessment, Health Care; Pneumonia, Ventilator-Associated; Retrospective Studies; Survival Analysis; United States | 2019 |